Translational Drug Development
@td2inc.com
TD2, a leading oncology CRO, advances oncology research by guiding new oncology therapies from preclinical and clinical trial phases to FDA approval.
Translational Drug Development's Company Logos
Translational Drug Development's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#0070BA
Lochmara
0, 112, 186
204, 100, 36
100, 40, 0, 27
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
#15447D
Chathams Blue
21, 68, 125
213, 71, 29
83, 46, 0, 51
About Translational Drug Development
**Brand Description for TD2 Precision Oncology**
TD2 Precision Oncology is a leading contract research organization (CRO) dedicated to advancing oncology therapies. Established in 2003 as a subsidiary of the Translational Genomics Research Institute (TGen), TD2 leverages cutting-edge resources and an extensive patient database to accelerate drug development for innovative biotech and pharmaceutical companies. The brand specializes in comprehensive clinical trial services, including Phase I, II, and III study design, planning, and execution—utilizing a data-driven approach to capture vital insights and early signals of response.
In addition to clinical capabilities, TD2 offers robust preclinical tools, encompassing over 400 cancer models and expertise in designing adaptive studies. The regulatory support team adeptly navigates the approval processes, ensuring successful IND development and FDA interactions. With advanced services like high-throughput flow cytometry, TD2 provides thorough insights into therapeutic efficacy, empowering clients to minimize risks and enhance their oncology products' success rate. With nearly two decades of experience, TD2 has supported over 850 companies in bringing groundbreaking cancer treatments to market.
